Search results for "LIVER TRANSPLANTATION"

showing 10 items of 359 documents

Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients

2014

Summary Background Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. Aim To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. Methods Analysis of the database from a prospective inception cohort of 494 patients. Decompensation was defined by ascites, bleeding, jaundice or encephalopathy. Explored potential prognostic stages: 1, compensated cirrhosis without oesophago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without other complications; 4, first nonbleeding decompensation; 5, any second decompensating event.…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaDatabases Factualmedicine.medical_treatmentLiver transplantationGastroenterologyCohort StudiesModel for End-Stage Liver DiseaseAscitesEsophageal and Gastric VariceMedicinePharmacology (medical)Prospective StudiesProspective cohort studyLiver NeoplasmsGastroenterologyAscitesJaundiceMiddle AgedPrognosisLiver NeoplasmAsciteDisease ProgressionFemalemedicine.symptomHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularPrognosiLiver CirrhosiJaundiceEsophageal and Gastric VaricesRisk AssessmentFollow-Up StudieInternal medicineHumansDecompensationAgedHepatologybusiness.industrymedicine.diseaseLiver TransplantationProspective StudieCohort StudiebusinessVaricesFollow-Up Studies
researchProduct

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.

2011

Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation. Patients with biopsies at 1 year after liver transplantation were evaluated by Ishak stage/grade, and biopsy samples stained with Sirius red for digital image analysis were evaluated for CPA. Cox regression was used to evaluate variables associated with first appearance of clinical decompensation. Receiver operating characteristic (ROC) curves were also used. A total of 135 patients with median follow-up of 76 months were evaluated. At 1…

Liver CirrhosisMaleCirrhosisTime FactorsPortal venous pressuremedicine.medical_treatmentBiopsyKaplan-Meier EstimateLiver transplantationmedicine.disease_causeGastroenterologyRecurrenceRisk FactorsLondonChildFirst episodemedicine.diagnostic_testMiddle AgedHepatitis CLiverFemaleCollagenAdultmedicine.medical_specialtyAdolescentHepatitis C virusHepatic VeinsRisk AssessmentSensitivity and SpecificityEnd Stage Liver DiseaseYoung AdultPredictive Value of TestsInternal medicineBiopsyImage Interpretation Computer-AssistedmedicineHumansDecompensationAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologybusiness.industrymedicine.diseaseSurgeryLiver TransplantationTransplantationROC CurveSurgerybusinessVenous PressureLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver tran…

2017

Sebastian Bernuth,1 Daniel Grimm,1 Johanna Vollmar,1 Felix Darstein,1 Jens Mittler,2 Michael Heise,2 Maria Hoppe-Lotichius,2 Peter R Galle,1 Hauke Lang,2 Tim Zimmermann1 1First Department of Internal Medicine, Transplant Hepatology, 2General-, Abdominal- and Transplant- Surgery, University Medical Center, Johannes Gutenberg University, Mainz, Germany Background: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT.Methods: We retrospe…

Liver CirrhosisMaleHepacivirusmedicine.medical_treatmentPharmaceutical ScienceHepacivirusLiver transplantationGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineRecurrenceDrug DiscoveryMedicine030212 general & internal medicineOriginal Researchbiologyliver transplantationvirus diseasesMiddle AgedTreatment OutcomeCohortHCV030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseCohort studymedicine.medical_specialtySVRAntiviral Agentsreinfection03 medical and health sciencesInternal medicineHumansSurvival analysisAgedRetrospective StudiesDAAPharmacologyDrug Design Development and Therapybusiness.industryRibavirinRetrospective cohort studyHepatitis C Chronicbiology.organism_classificationVirologySurvival Analysisdigestive system diseasesDiscontinuationchemistrybusinessDrug design, development and therapy
researchProduct

Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy

2020

Abstract Background and aims Nonalcoholic steatohepatitis (NASH) may progress to advanced liver disease (AdvLD). This study characterized comorbidities, healthcare resource utilization (HCRU) and associated costs among hospitalized patients with AdvLD due to NASH in Italy. Methods and results Adult nonalcoholic fatty liver disease (NAFLD)/NASH patients from 2011 to 2017 were identified from administrative databases of Italian local health units using ICD-9-CM codes. Development of compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), or liver transplant (LT) was identified using first diagnosis date for each severity cohort (index-date). Patients progres…

Liver CirrhosisMaleTime FactorsCirrhosisDatabases FactualEndocrinology Diabetes and MetabolismMedicine (miscellaneous)ComorbidityHospital Cost030204 cardiovascular system & hematologyLiver diseasePatient Admission0302 clinical medicineRetrospective StudieNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAmbulatory CarePrevalenceMedicineHospital Costseducation.field_of_studyDrug CostNutrition and DieteticsLiver NeoplasmsNASHMiddle AgedPrognosisItalyLiver NeoplasmHepatocellular carcinomaCohortDisease ProgressionHealth ResourcesFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularTime FactorAdolescentCostPrognosiLiver CirrhosiPopulation030209 endocrinology & metabolismPharmacyDrug CostsYoung Adult03 medical and health sciencesNAFLDInternal medicineHumanseducationAgedRetrospective StudiesHealth Resourcebusiness.industryRisk Factormedicine.diseaseComorbiditydigestive system diseasesLiver TransplantationHCRUbusinessAdministrative Claims HealthcareNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir.

2013

Haemophagocytic syndrome (HS) is a rare disease that is often fatal despite treatment. HS is characterized by fevers, lymphadenopathy, hepatosplenomegaly, cytopenias and hyperferritinaemia due to deregulated activation and proliferation of macrophages, leading to uncontrolled phagocytosis of platelets, erythrocytes, lymphocytes, and their hematopoietic precursors throughout the reticuloendothelial system. Mycobacterium tuberculosis-associated HS is a rare and underdiagnosed association with only 39 cases reported. We describe a case of HS associated with disseminated Mycobacterium tuberculosis in the setting of post-liver transplantation anti-hepatitis C therapy with pegylated interferon (p…

Liver CirrhosisMaleTuberculosisTime Factorsmedicine.medical_treatmentHepatosplenomegalyAntitubercular AgentsSpecialties of internal medicineHepacivirusLiver transplantationVHCAntiviral AgentsLymphohistiocytosis HemophagocyticTelaprevirTelaprevirchemistry.chemical_compoundFatal OutcomePegylated interferonRisk FactorsmedicineHumansTuberculosisHepatologyHaemophagocytic syndromebusiness.industryRibavirinGeneral MedicineMycobacterium tuberculosisMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationTransplantationchemistryRC581-951ImmunologyDrug Therapy CombinationVirus Activationmedicine.symptombusinessOligopeptidesImmunosuppressive Agentsmedicine.drugRare diseaseAnnals of hepatology
researchProduct

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrho…

2018

Background: In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this “real-life” study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV). Methods: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post-treatment (SVR12). Results: Eighty-seven patients were enrolled (75.9% males, mean age 58.4 ±…

Liver CirrhosisMalehepatitis C virusPyrrolidinesCirrhosisSofosbuvirmedicine.medical_treatmentantiviral treatmentHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrencehepatitis C viruProspective StudiesProspective cohort studySettore MED/12 - Gastroenterologialiver transplantationdirect antiviral agentsImidazolesValineHepatitis CMiddle AgedPrognosisHepatitis CItalyHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyDaclatasvirHepatitis C virusAntiviral Agentsantiviral treatment; cirrhosis; direct antiviral agents; hepatitis C virus; liver transplantation03 medical and health sciencesInternal medicineRibavirinmedicineHumansTransplantationdirect antiviral agentbusiness.industryRibavirincirrhosismedicine.diseasechemistryCarbamatesSofosbuvirbusinessFollow-Up Studiescirrhosi
researchProduct

Efficacy of an escalating dose regimen of pegylated interferon ?-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

2007

We evaluated the safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2a (PEG-IFN(alpha-2a)) and ribavirin in the early phase of recurrent hepatitis C after orthotopic liver transplantation (OLT). In this prospective study, 26 patients transplanted for hepatitis C virus cirrhosis with recurrent hepatitis C were treated 3.4 +/- 3.6 months after OLT and compared with an untreated historical control. PEG-IFN(alpha-2a) was initiated as monotherapy, following stepwise dose escalation up to 180 mug/week and the addition of ribavirin up to 1200 mg/day or maximally tolerated doses for 48 weeks. In the intent-to-treat analysis, 38% showed an early virological response (EVR…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene GlycolsCohort Studieschemistry.chemical_compoundPostoperative ComplicationsPegylated interferonRecurrenceInternal medicineRibavirinmedicineHumansAdverse effectAgedTransplantationbusiness.industryRibavirinInterferon-alphaAlanine TransaminaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsLiver TransplantationRegimenTreatment OutcomechemistryImmunologyRNA ViralFemalebusinessmedicine.drugTransplant International
researchProduct

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

2020

INTRODUCTION: Despite the negative impact of covert hepatic encephalopathy on the outcome of patients with liver cirrhosis, data regarding the ability of different testing strategies to predict overt hepatic encephalopathy (OHE) development and mortality are limited. This study aimed to compare the ability of Psychometric Hepatic Encephalopathy Score (PHES), critical flicker frequency (CFF), simplified animal naming test (S-ANT1), and clinical covert hepatic encephalopathy (CCHE) score to predict OHE development and mortality. METHODS: A total of 224 patients with liver cirrhosis were tested with different testing strategies and prospectively followed up regarding clinically relevant outcom…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationRisk AssessmentSeverity of Illness IndexArticleEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicinePredictive Value of TestsInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyHepatic encephalopathyAgedReceiver operating characteristicbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsHepatic EncephalopathyFeasibility Studies030211 gastroenterology & hepatologyFemalebusinessFollow-Up StudiesClinical and Translational Gastroenterology
researchProduct

Liver stiffness measurement in patients with nodular regenerative hyperplasia undergoing magnetic resonance elastography

2020

Purpose Nodular regenerative hyperplasia (NRH) may mimic cirrhosis at imaging. We aim to investigate the effect of NRH on liver stiffness measurement (LSM) obtained with magnetic resonance elastography (MRE).Methods This retrospective, Institutional Review Board-approved study included 37 subjects with NRH (Group 1) and no or minimal fibrosis (F0-F1), a control group (Group 2) made of 30 subjects with non-advanced fibrosis (F0-F2), and a control group (Group 3) made of 30 subjects with advanced fibrosis (F3-F4), all with available MRE. LSM was measured in each subject along with assessment of hepatic morphological features of cirrhosis and signs of portal hypertension. The significance of t…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisUrologyContrast MediaGastroenterology030218 nuclear medicine & medical imagingDiagnosis Differential03 medical and health sciencessymbols.namesakeMeglumineMagnetic resonance imaging0302 clinical medicineFibrosisInternal medicineOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingFisher's exact testAgedRetrospective StudiesHyperplasiaRadiological and Ultrasound Technologymedicine.diagnostic_testNodular regenerative hyperplasiabusiness.industryGastroenterologyMagnetic resonance imagingMiddle AgedHepatologymedicine.diseaseLiver RegenerationLiver TransplantationMagnetic resonance elastographyLiverMagnetic resonance elastography030220 oncology & carcinogenesissymbolsElasticity Imaging TechniquesPortal hypertensionFemalebusinessLiver diseaseNodular regenerative hyperplasiaAbdominal Radiology
researchProduct

Hemodynamic changes in splanchnic circulation after orthotopic liver transplantation in patients with liver cirrhosis

2002

Background: Liver cirrhosis increases portal vein pressure and alters the splanchnic circulation. With Doppler sonography, we investigated the hemodynamic changes in the portal vein, superior mesenteric artery, hepatic and splenic arteries and spleen size in a group of patients with end-stage liver disease before and after orthotopic liver transplantation (OLT). Methods: Ten patients (seven male, three female; mean age = 48.8 ± 7.6 years) who underwent OLT for liver cirrhosis mainly associated with hepatitis C virus infection completed the study. The control group consisted of 10 patients matched by sex and age who had no gastroenterologic or vascular diseases. All patients underwent duplex…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisUrologyPortal venous pressuremedicine.medical_treatmentHepatic VeinsSplenic arteryLiver transplantationLiver cirrhosiLiver diseaseMesenteric Artery SuperiorInternal medicinemedicine.arteryHumansMedicineRadiology Nuclear Medicine and imagingSplanchnic CirculationUltrasonography Doppler ColorDuplex DopplerFibrous capsule of GlissonRadiological and Ultrasound TechnologyPortal Veinbusiness.industrySplanchnic CirculationHemodynamic changeGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseLiver TransplantationSurgeryTransplantationsurgical procedures operativecardiovascular systemCardiologyFemaleVascular ResistancebusinessSplenic ArteryBlood Flow VelocitySpleenAbdominal Imaging
researchProduct